Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
We have examined the effect of chronic (4 wk) hyperglycemia on insulin secretion in vivo in an awake, unstressed rat model. Three groups of animals were examined: control, partial (90%) pancreatectomy, and partial pancreatectomy plus phlorizin, in order to normalize plasma glucose levels. Insulin secretion in response to arginine (2 mM), hyperglycemia (+100 mg/dl), and arginine plus hyperglycemia was evaluated. In diabetic compared with control animals three specific alterations were observed: (a) a deficient insulin response, in both first and second phases, to hyperglycemia; (b) an augmented insulin response to the potentiating effect of arginine under basal glycemic conditions; and (c) an inability of hyperglycemia to augment the potentiating effect of arginine above that observed under basal glycemic conditions. Normalization of the plasma glucose profile by phlorizin treatment in diabetic rats completely corrected all three beta cell abnormalities. These results indicate that chronic hyperglycemia can lead to a defect in in vivo insulin secretion which is reversible when normoglycemia is restored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationKolterman, O. G., Gray, R. S., Griffin, J., Burstein, P., Insel, J., Scarlett, J. A., & Olefsky, J. M. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110350 · Cited by 629
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488
Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release.
Bonner-Weir, S., Trent, D. F., & Weir, G. C. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110910 · Cited by 467
Mechanism of glucose-induced insulin secretion.
Hedeskov, C. J. (1980) · Physiological Reviews · doi:10.1152/physrev.1980.60.2.442 · Cited by 435
Insulin secretion in diabetes mellitus
Pfeifer, M. A., Halter, J. B., & Porte, D. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90579-9 · Cited by 367
The pancreatic islets in diabetes
Gepts, W., & Lecompte, P. M. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90417-4 · Cited by 349
Henry, R. R., Wallace, P., & Olefsky, J. M. (1986) · Diabetes · doi:10.2337/diab.35.9.990 · Cited by 325 · cited 1×
“Thus, acute (41) and chronic (42) caloric restriction, intensified insulin therapy (43), and sulfonylurea drugs (44, 45) all result in a significant lowering of the plasma glucose concentration and a concomitant increase in insulin secretion which may be sustained even after the therapy is”
Background
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationIslet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
“More direct support of the glucotoxicity hypothesis comes from animal studies in which diabetic rats were treated with phlorizin, a potent renal tubular glucose transporter inhibitor that reduces the plasma glucose concentration without altering other circulating substrate levels [68].”
Self-citationEhrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationPolonsky, K. S., Sturis, J., & Bell, G. I. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341207 · Cited by 595
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
Jonas, J.-C., Sharma, A., Hasenkamp, W., Ilkova, H., Patanè, G., Laybutt, R., Bonner-Weir, S., & Weir, G. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14112 · Cited by 559
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515
Self-citationThe role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
Self-citationPathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Self-citationRosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., Capuano, G., Canovatchel, W., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 421
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Santer, R., & Calado, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 343
Regulation of Blood Glucose by Hypothalamic Pyruvate Metabolism
Lam, T. K. T., Gutierrez-Juarez, R., Pocai, A., & Rossetti, L. (2005) · Science · doi:10.1126/science.1112085 · Cited by 341
Self-citationDevelopment of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationCohen, N., Halberstam, M., Shlimovich, P., Chang, C. J., Shamoon, H., & Rossetti, L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117951 · Cited by 327
Self-citationDel Prato, S., Leonetti, F., Simonson, D. C., Sheehan, P., Matsuda, M., & DeFronzo, R. A. (1994) · Diabetologia · doi:10.1007/bf00400466 · Cited by 322
“Sustained hyperglycaemia has been shown to impair insulin secretion [23, 24] and to induce insulin resistance [1, 25].”
BackgroundSelf-citationMaggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Self-citationBensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0473 · Cited by 263
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
“Phlorizin, a nonselective inhibitor of SGLT1 and SGLT2, reduces BG in preclinical models of T2DM [9] and, due to its insulin-independent mechanism of action, also lowers BG in models of type 1 diabetes [9,10].”
BackgroundMolecular disruption of hypothalamic nutrient sensing induces obesity
He, W., Lam, T. K. T., Obici, S., & Rossetti, L. (2006) · Nature Neuroscience · doi:10.1038/nn1626 · Cited by 233
“In rats subjected to the pancreatic insulin-clamp protocols, additional catheters were placed in the right internal jugular and left carotid artery 1 week before the stud”
Self-citationSodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
“Experiments by Rossetti and colleagues in diabetic rats demonstrated that sustained phlorizin treatment normalized blood glucose concentrations resulting in reduced “glucotoxicity” and improvements in b-cell function and insulin sensitivity (24,25).”
BackgroundPhasic Insulin Release and Metabolic Regulation in Type 2 Diabetes
Del Prato, S., Marchetti, P., & Bonadonna, R. C. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s109 · Cited by 223
“These results may appear to be in contrast to animal studies where a similar duration (72 h) of hyperglycemia was shown to impair insulin secretion (22,23).”
ResultDel Prato, S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 197
Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drug
Idris, I., & Donnelly, R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00982.x · Cited by 181
Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A. (2012) · Diabetes · doi:10.2337/db11-0995 · Cited by 122
“Conversely, improving glycemic control in type 2 diabetic subjects with insulin therapy improves b-cell function (27), and experimental studies in animals (28–30) have reported that a small rise (16 mg/dL) in FPG concentration is associated with a marked inhibition of glucose-stimulated insulin secretion, whereas corr…”
BackgroundSelf-citationFavourable metabolic effects of a eucaloric lower‐carbohydrate diet in women with PCOS
Gower, B. A., Chandler‐Laney, P. C., Ovalle, F., Goree, L. L., Azziz, R., Desmond, R. A., Granger, W. M., Goss, A. M., & Bates, G. W. (2013) · Clinical Endocrinology · doi:10.1111/cen.12175 · Cited by 108
Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.
Greenbaum, C. J., Havel, P. J., Taborsky, G. J., & Klaff, L. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115375 · Cited by 106
Gower, B. A., & Goss, A. M. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.195065 · Cited by 98
Abdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00674.2007 · Cited by 91
Self-citationAN INTEGRATED VIEW OF β-CELL DYSFUNCTION IN TYPE-II DIABETES
Poitout, D., & Robertson, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.69 · Cited by 62
Delghingaro-Augusto, V., Nolan, C. J., Gupta, D., Jetton, T. L., Latour, M. G., Peshavaria, M., Madiraju, S. R. M., Joly, É., Peyot, M.-L., Prentki, M., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1317-8 · Cited by 57
Metadata
- Authors
- Rossetti, L., Shulman, G. I., Zawalich, W., & DeFronzo, R. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1987-10-01
- Volume
- 80
- Issue
- 4
- Pages
- 1037-1044
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2102348011
- Cited by
- 330
- References
- 38
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.